Doxorubicin Cardiomyopathy
نویسندگان
چکیده
منابع مشابه
Inorganic Nitrate Therapy Improves Doxorubicin-Induced Cardiomyopathy
The anthracycline doxorubicin (DOX) is a potent and effective antineoplastic antibiotic agent widely used in the treatment of a broad range of forms of cancer. The clinical use of DOX is limited by cardiotoxicity, which increases dose dependently and may lead to dilated cardiomyopathy and clinical manifestations of congestive heart failure up to 10 to 15 years after the cessation of DOX chemoth...
متن کاملBovine Model of Doxorubicin-Induced Cardiomyopathy
Left ventricular assist devices (LVADs) constitute a recent advance in heart failure (HF) therapeutics. As the rigorous experimental assessment of LVADs in HF requires large animal models, our objective was to develop a bovine model of cardiomyopathy. Male calves (n = 8) were used. Four animals received 1.2 mg/kg intravenous doxorubicin weekly for seven weeks and four separate animals were stud...
متن کاملCarvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy.
Several cytopathic mechanisms have been suggested to mediate the dose-limiting cumulative and irreversible cardiomyopathy caused by doxorubicin. Recent evidence indicates that oxidative stress and mitochondrial dysfunction are key factors in the pathogenic process. The objective of this investigation was to test the hypothesis that carvedilol, a nonselective beta-adrenergic receptor antagonist ...
متن کاملan ovine model of dilated cardiomyopathy induced by doxorubicin
background: dilated cardiomyopathy is associated with a progressive deterioration in cardiac function and eventually death. initial interest in this hypothesis was to create another large animal model for dilated cardiomyopathy in addition to pigs and dogs . methods: after the induction of anesthesia to 10 female sheep, a carotid-jugular shunt was created in all the animals via a 1-cm fistula b...
متن کاملAggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicin.
There is a dose-effect relationship between doxorubicin and the incidence of symptomatic cardiac failure. It is generally thought that doses below 500-550 mg/m2 are safe but, when objective measures of cardiac function are used, it becomes apparent that degrees of cardiac failure occur at doses below this. We present here the case histories of two patients who developed very severe cardiac fail...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cardiology
سال: 2010
ISSN: 1421-9751,0008-6312
DOI: 10.1159/000265166